Henry G. Grabowski
About
In The Last Decade
Henry G. Grabowski
98 papers receiving 8.7k citations
Hit Papers
Peers
Comparison fields: 5 of 188
- Economics and Econometrics 5.6k
- Management of Technology and Innovation 1.7k
- Molecular Biology 1.5k
- Public Health, Environmental and Occupational Health 1.2k
- Computational Theory and Mathematics 1.2k
Countries citing papers authored by Henry G. Grabowski
This map shows the geographic impact of Henry G. Grabowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry G. Grabowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry G. Grabowski more than expected).
Fields of papers citing papers by Henry G. Grabowski
This network shows the impact of papers produced by Henry G. Grabowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry G. Grabowski. The network helps show where Henry G. Grabowski may publish in the future.
Co-authorship network of co-authors of Henry G. Grabowski
This figure shows the co-authorship network connecting the top 25 collaborators of Henry G. Grabowski. A scholar is included among the top collaborators of Henry G. Grabowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry G. Grabowski. Henry G. Grabowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 1 | |
| 3 | Innovation in the pharmaceutical industry: New estimates of R&D costs breakdown → | 1948 |
| 4 | Consumer Product Safety Regulation | 0 |
| 5 | Pharmaceutical Patent Challenges and Their Implications for Innovation and Generic Competition | 1 |
| 6 | Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act | 1 |
| 7 | 49 | |
| 8 | 22 | |
| 9 | Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures | 8 |
| 10 | 65 | |
| 11 | The price of innovation: new estimates of drug development costs breakdown → | 2642 |
| 12 | RETURNS ON R&D FOR 1990s NEW DRUG INTRODUCTIONS | 6 |
| 13 | 191 | |
| 14 | The impact of cost-effectiveness on public and private policies in health care: an international perspective | 7 |
| 15 | 72 | |
| 16 | Longer Patents for Increased Genetic Competition: The Waxman-Hatch Act After One Decade | 8 |
| 17 | Health Reform and Pharmaceutical Innovation | 15 |
| 18 | 440 | |
| 19 | Substitution laws and innovation in the pharmaceutical industry. | 13 |
| 20 | The Effects of Advertising on the Interindustry Distribution of Demand | 27 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.